MedTrace Logo

Extracorporeal Blood Purification as a Treatment Modality for COVID-19

NCT04478539 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2022-12-01

No results posted yet for this study

Summary

Several studies have suggested a potential clinical benefit of controlling hyper inflammation triggered by SARS-CoV-2/COVID-19. Blood purification, the removal of excessive proinflammatory mediators may control disease progression and support clinical recovery.

For this purpose, COVID-19 patients might benefit from treatment with AN69ST hemofilter based extracorporeal blood purification.

Conditions

  • Covid19

Interventions

DEVICE

Extracorporeal blood purification using the oXiris® (AN69ST) hemofilter

Admitted patients will receive at least 1 cycle of extracorporeal blood purification using the oXiris® (AN69ST) hemofilter (Baxter, IL, USA). The number of cycles of blood purification is determined based on multiple biochemical, immunological, coagulation parameters, radiological imaging and overall clinical condition. The patient is connected to the Prismaflex® oXiris® system via a double lumen catheter placed in the femoral vein or vena subclavia. Flow rates will be maintained as follow; effluent dose 35 mL/Kg/h, dialysate 14 - 16 mL/Kg/h, blood 150 mL/min, replacement 16 -18 mL/Kg/h; patient fluid removal is tailored to the individual's volume status, ≈ 100 - 250 mL/h. The oXiris® extracorporeal and organ support modality will be chosen according to the patient's kidney function; continuous venovenous hemofiltration (CVVH), continuous venovenous hemodiafiltration (CVVHDF) or slow continuous ultrafiltration (SCUF).

Sponsors & Collaborators

  • Zan Mitrev Clinic

    lead OTHER

Principal Investigators

  • Zan K Mitrev, MD · Zan Mitrev Clinic

  • Rodney A Rosalia, PhD · Zan Mitrev Clinic

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2021-07-01
Completion
2021-07-01
FDA Device
Yes

Countries

  • North Macedonia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04478539 on ClinicalTrials.gov